Literature DB >> 16173326

Relationship between C peptide and chronic complications in type-2 diabetes mellitus.

Ramazan Sari1, Mustafa Kemal Balci.   

Abstract

OBJECTIVE: The relationship between C peptide and micro- and macrovascular complications is poorly known in type-2 diabetes mellitus. The aim of the study was to evaluatethe relationship between serum C-peptide level and chronic complications in patients with type-2 diabetes mellitus. PATIENTS AND METHODS: Three-hundred-eighteen patients (138 male, 180 female) with type-2 diabetes mellitus were included in the study. Microvascular (nephropathy, retinopathy and neuropathy) and macrovascular complications (coronary artery disease and peripheral vascular disease) were determined in all patients. In addition, presence of hypertension and smoking habit was recorded. Fasting serum glucose, lipid levels, HbA1c and C-peptide levels were measured in all patients.
RESULTS: There were 90 (28.3%) patients with sensorial neuropathy, 48 (15.1%) with autonomic neuropathy, 72 (22.7%) with nephropathy, 84 (26.4%) with retinopathy, 135 (42.5%) with hypertension, 270 (84.9%) with dyslipidemia, 33 (10.4%) with coronary artery disease and 18 (5.7%) with peripheral vascular disease. Serum C-peptide level was higher in patients with dyslipidemia (p = 0.045), hypertension (p = 0.001), coronary artery disease (p = 0.001), peripheral vascular disease (p = 0.001) and autonomic neuropathy (p = 0.001). Serum C-peptide level was not significantly different in patients with and without sensorial neuropathy, nephropathy and retinopathy. Serum C-peptide level was significantly associated with the presence of coronary artery disease (p = 0.001), peripheral vascular disease (p = 0.001) and autonomic neuropathy (p = 0.001). There was no relationship between C peptide and sensorial neuropathy, nephropathy and retinopathy.
CONCLUSION: Our findings indicate a relationship between C peptide and macrovascular but not microvascular compli cations in patients with type-2 diabetes mellitus.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16173326      PMCID: PMC2575980     

Source DB:  PubMed          Journal:  J Natl Med Assoc        ISSN: 0027-9684            Impact factor:   1.798


  38 in total

Review 1.  Genetics of diabetic nephropathy and microalbuminuria.

Authors:  S C Bain; T A Chowdhury
Journal:  J R Soc Med       Date:  2000-02       Impact factor: 5.344

2.  Circulating C-peptide and diabetic retinopathy.

Authors:  M A Mosier
Journal:  Diabetes Res       Date:  1984-09

3.  C-peptide prevents glomerular hypertrophy and mesangial matrix expansion in diabetic rats.

Authors:  Björn Samnegård; Stefan H Jacobson; Georg Jaremko; Bo-Lennart Johansson; Karin Ekberg; Britta Isaksson; Linda Eriksson; John Wahren; Mats Sjöquist
Journal:  Nephrol Dial Transplant       Date:  2005-01-21       Impact factor: 5.992

4.  The value of cardiovascular autonomic function tests: 10 years experience in diabetes.

Authors:  D J Ewing; C N Martyn; R J Young; B F Clarke
Journal:  Diabetes Care       Date:  1985 Sep-Oct       Impact factor: 19.112

5.  C-peptide response to glucagon in diabetics with and without complications.

Authors:  R B Smith; D A Pyke; P J Watkins; C Binder; O K Faber
Journal:  N Z Med J       Date:  1979-04-25

6.  High serum insulin concentrations in relation to other cardiovascular risk factors in macrovascular disease of type 2 diabetes.

Authors:  E Standl; H U Janka
Journal:  Horm Metab Res Suppl       Date:  1985

7.  Increased incidence of retinopathy in diabetics with elevated blood pressure. A six-year follow-up study in Pima Indians.

Authors:  W C Knowler; P H Bennett; E J Ballintine
Journal:  N Engl J Med       Date:  1980-03-20       Impact factor: 91.245

8.  Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes.

Authors:  C E Mogensen
Journal:  N Engl J Med       Date:  1984-02-09       Impact factor: 91.245

9.  Kidney function during 12 months of strict metabolic control in insulin-dependent diabetic patients with incipient nephropathy.

Authors:  B Feldt-Rasmussen; E R Mathiesen; L Hegedüs; T Deckert
Journal:  N Engl J Med       Date:  1986-03-13       Impact factor: 91.245

10.  Differential responsiveness to insulin of endothelial and support cells from micro- and macrovessels.

Authors:  G L King; S M Buzney; C R Kahn; N Hetu; S Buchwald; S G Macdonald; L I Rand
Journal:  J Clin Invest       Date:  1983-04       Impact factor: 14.808

View more
  15 in total

Review 1.  C-Peptide and its career from innocent bystander to active player in diabetic atherogenesis.

Authors:  Corinna Lebherz; Nikolaus Marx
Journal:  Curr Atheroscler Rep       Date:  2013-07       Impact factor: 5.113

2.  Association of C-peptide and lipoprotein(a) as two predictors with cardiometabolic biomarkers in patients with type 2 diabetes in KERCADR population-based study.

Authors:  Mohammad Reza Mahmoodi; Hamid Najafipour
Journal:  PLoS One       Date:  2022-05-24       Impact factor: 3.752

3.  C-peptide levels and the risk of diabetes and pre-diabetes among Chinese women with gestational diabetes.

Authors:  Ping Yin; Ping Shao; Huikun Liu; Weiqin Li; Leishen Wang; Jing Wang; Shuang Zhang; Junhong Leng; Nan Li; Huiguang Tian; Xilin Yang; Zhijie Yu; Gang Hu
Journal:  J Diabetes Complications       Date:  2017-08-17       Impact factor: 2.852

4.  Proinflammatory effects of C-Peptide in different tissues.

Authors:  Dusica Vasic; Daniel Walcher
Journal:  Int J Inflam       Date:  2012-06-11

Review 5.  The clinical utility of C-peptide measurement in the care of patients with diabetes.

Authors:  A G Jones; A T Hattersley
Journal:  Diabet Med       Date:  2013-07       Impact factor: 4.359

6.  Association of fasting insulin and C peptide with diabetic retinopathy in Latinos with type 2 diabetes.

Authors:  Jane Z Kuo; Xiuqing Guo; Ronald Klein; Barbara E Klein; Robert N Weinreb; Pauline Genter; Fone-Ching Hsiao; Mark O Goodarzi; Jerome I Rotter; Yii-Der Ida Chen; Eli Ipp
Journal:  BMJ Open Diabetes Res Care       Date:  2014-10-24

Review 7.  Proinsulin C-peptide: friend or foe in the development of diabetes-associated complications?

Authors:  Lina Nordquist; M Johansson
Journal:  Vasc Health Risk Manag       Date:  2008

8.  Renal and vascular benefits of C-peptide: Molecular mechanisms of C-peptide action.

Authors:  Lina Nordquist; Fredrik Palm; Bradley T Andresen
Journal:  Biologics       Date:  2008-09

9.  C-Peptide and vascular complications in type 2 diabetic subjects.

Authors:  Seok Man Son
Journal:  Diabetes Metab J       Date:  2012-10-18       Impact factor: 5.376

10.  Correlations between Glucagon Stimulated C-peptide Levels and Microvascular Complications in Type 2 Diabetes Patients.

Authors:  Hye-Jin Yoon; Youn-Zoo Cho; Ji-Young Kim; Byung-Joon Kim; Keun-Young Park; Gwan-Pyo Koh; Dae-Ho Lee; Dong-Mee Lim
Journal:  Diabetes Metab J       Date:  2012-10-18       Impact factor: 5.376

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.